What Does “CJC-1295 With DAC” Mean in Research?

“CJC-1295 with DAC” is a later clarification commonly used to identify the albumin-binding form of CJC-1295. In the original research literature, the compound called CJC-1295 already contained a C-terminal reactive structure designed for covalent albumin association. The added phrase “with DAC” therefore helps distinguish that original albumin-binding molecular design from the separate non-DAC peptide commonly called Modified GRF (1-29).

This naming distinction supports the broader identity framework in CJC-1295 Research. Research articles should specify the actual structure rather than assuming that the words CJC-1295, DAC, no DAC, and Modified GRF (1-29) are interchangeable.

Research-use notice: InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.

What Does DAC Mean?

DAC is commonly expanded as Drug Affinity Complex in CJC-1295-related terminology.

The phrase refers to a molecular design strategy intended to create covalent association between the modified peptide and circulating albumin.

DAC is not:

• a second peptide
• a hormone
• a receptor
• a separate injectable ingredient

The DAC Concept Is Structural

The defining feature involves a reactive chemical group built into the peptide structure.

In the original CJC-1295 design, this group is associated with:

• a C-terminal lysine
• a maleimide-containing moiety
• thiol-reactive chemistry
• albumin bioconjugation

CJC-1295 With DAC Is Not a Mixture of CJC-1295 Plus DAC

The phrase can sound as though DAC is an additive combined with a finished peptide.

That is misleading.

The albumin-binding functionality is chemically incorporated into the molecule itself.

The Original CJC-1295 Already Contained the DAC-Related Design

The earliest peer-reviewed CJC-1295 papers describe an albumin-binding conjugation strategy as part of the compound.

Therefore, “with DAC” is largely later clarifying terminology rather than evidence that an optional component was added to an otherwise identical original CJC-1295 molecule.

Why the Clarifying Phrase Became Useful

Later peptide-market terminology began using phrases such as:

• CJC-1295 DAC
• CJC-1295 with DAC
• CJC-1295 without DAC
• CJC-1295 no DAC

This created a need to distinguish structurally different materials sharing similar names.

DAC Presence Changes Molecular Identity

A peptide carrying the C-terminal DAC-associated structure is chemically different from the 29-residue peptide without that extension.

Differences can include:

• sequence length
• molecular mass
• chemical reactivity
• albumin association
• analytical profile

The Defined CJC-1295 Structure Includes 30 Residues

Current FDA substance information for CJC-1295 lists a 30-residue sequence.

The final residue is a lysine carrying the maleimide-related modification.

This distinguishes the defined CJC-1295 substance from the 29-residue modified GRF backbone.

Why a C-Terminal Lysine Was Added

The added lysine provides a side-chain functional group that can carry the reactive conjugated structure.

This makes the residue part of the albumin-binding molecular design rather than merely an unmodified sequence extension.

Maleimide Chemistry Is Central to the DAC Concept

Maleimides can react selectively with suitable thiol groups under defined chemical conditions.

Albumin contains a reactive cysteine-associated thiol that can participate in this chemistry.

This made albumin a target for the bioconjugation strategy used in CJC-1295 research.

What Does Albumin Bioconjugation Mean?

Bioconjugation refers to formation of a chemical linkage between a designed molecule and a biological macromolecule.

In CJC-1295 research, investigators examined formation of peptide-albumin-associated species after exposure to biological systems.

Covalent Association Is Different From Ordinary Protein Binding

Some peptides interact reversibly with albumin through non-covalent forces.

The CJC-1295 DAC concept instead uses reactive chemistry capable of forming a covalent bond.

Researchers should distinguish these mechanisms.

Why Albumin Was Used as a Research Target

Albumin circulates at relatively high concentrations and has a prolonged residence time within circulation.

Attaching a peptide-associated structure to albumin can substantially change the peptide's apparent pharmacokinetic behaviour.

This is a molecular-design rationale rather than a statement about clinical benefit.

DAC Terminology Is Closely Connected to Pharmacokinetics

Early CJC-1295 research investigated whether albumin association altered circulating persistence.

Pharmacokinetic variables included:

• compound-associated concentration
• apparent half-life
• duration of detection
• area under the concentration-time curve

Pharmacokinetics Does Not Establish Effectiveness

A prolonged concentration-time profile describes compound exposure.

It does not independently establish:

• greater effectiveness
• better outcomes
• greater safety
• greater suitability

Longer Persistence Is Not a Universal Advantage

A longer measurable duration may be relevant to one experimental objective and undesirable or irrelevant to another.

Research interpretation should therefore describe the measured pharmacokinetic property rather than calling it inherently better.

Albumin Association Can Affect Analytical Measurement

When a peptide becomes protein associated, assay development may need to consider:

• free material
• protein-bound material
• sample extraction
• antibody recognition
• mass-spectrometric recovery

Analytical methods developed for free peptide may not measure every associated molecular form equally.

Immunoreactivity Does Not Necessarily Establish Intact Structure

An antibody-based assay may recognize an epitope within free or albumin-associated material.

Detection should therefore be interpreted according to:

• assay specificity
• epitope location
• cross-reactivity
• sample preparation

Mass Spectrometry Can Add Structural Information

Mass-spectrometric methods can help characterize:

• free peptide
• modified peptide
• degradation products
• conjugated molecular species

The exact analytical strategy depends on the size and complexity of the species being studied.

DAC Does Not Mean Receptor Potency

The DAC designation describes structural and pharmacokinetic design.

It does not independently specify:

• GHRH-receptor potency
• maximal receptor response
• receptor selectivity

Receptor Pharmacology and DAC Chemistry Are Separate Dimensions

The peptide backbone contributes to GHRH-receptor-associated pharmacology.

The DAC-related structure contributes to albumin association and altered exposure.

Both can be relevant to the same compound without being the same property.

DAC Does Not Mean Growth Hormone

Growth hormone is a downstream pituitary protein hormone.

DAC is part of the structural terminology of CJC-1295.

The two should not be confused.

DAC Does Not Mean IGF-I

IGF-I is another downstream molecule measured in some endocrine studies.

It is not a component of the CJC-1295 structure.

CJC-1295 DAC and Native GHRH Are Still Different Molecules

Albumin-binding CJC-1295 is an engineered synthetic analog.

Native GHRH does not contain the same:

• modified 1-29 backbone
• C-terminal lysine extension
• maleimide-associated group

CJC-1295 DAC and Modified GRF (1-29) Are Also Different

Modified GRF (1-29) represents the related tetrasubstituted 29-residue peptide without the same DAC-associated C-terminal extension.

The two names should therefore not be swapped casually.

Why “With DAC” Is More Precise in Mixed Commercial Contexts

Because CJC-1295 terminology became inconsistent outside the original literature, adding “with DAC” can clarify that the albumin-binding molecular form is intended.

However, researchers should still verify:

• sequence
• terminal modification
• molecular mass
• salt form
• analytical identity

A DAC Label Does Not Establish Structural Confirmation

A commercial description stating “with DAC” is still only a label until molecular evidence supports the claim.

Useful identity methods may include:

• mass spectrometry
• chromatography
• sequence information
• structural documentation

Purity Does Not Establish DAC Identity

A high chromatographic purity result does not establish that the major component contains the expected albumin-binding modification.

Identity and purity answer separate analytical questions.

DAC Free Base and DAC Salt Forms Are Additional Categories

FDA materials distinguish multiple CJC-1295 DAC-related forms, including:

• CJC-1295 DAC free base
• CJC-1295 DAC acetate
• CJC-1295 DAC trifluoroacetate

These counterion distinctions create another layer of molecular specification.

Salt Form Can Affect Analytical Interpretation

Counterions can influence:

• reported material mass
• molecular-weight calculations
• pH
• residual-processing measurements
• formulation characterization

FDA Has Reviewed CJC-1295-Related Forms Separately

FDA's 2024 Pharmacy Compounding Advisory Committee materials explicitly listed CJC-1295-related substances as separate free-base, acetate, DAC free-base, DAC acetate, and DAC trifluoroacetate forms.

This regulatory-review structure illustrates why one broad CJC-1295 label cannot resolve every molecular form.

FDA Review Does Not Mean Approval

Consideration of a bulk drug substance by an advisory committee is not equivalent to FDA approval of a drug product.

The regulatory context should therefore be stated accurately.

FDA Also Identified Evidence Gaps

FDA briefing materials reviewing CJC-1295-related bulk substances distinguished DAC-associated forms from non-DAC forms and noted substantial limitations in the available evidence, including differences in the amount of nonclinical information available across forms.

These observations reinforce the need to keep molecular forms separate rather than transferring evidence between them.

Human CJC-1295 Research Should Be Matched to the DAC Form

Published human research commonly cited for CJC-1295 arose from the albumin-binding development program.

That evidence should not be assigned automatically to a non-DAC Modified GRF (1-29) material.

Study Formulation Matters

A controlled study uses a defined investigational preparation.

A separately sourced material with a similar name does not automatically share:

• identity
• purity
• DAC modification
• counterion form
• formulation

Clinical Protocols Do Not Become Use Instructions

Experimental amounts and schedules reported in CJC-1295 studies belong to those study protocols.

They should not be converted into personal-use guidance.

“With DAC” Should Not Be Used as a Benefit Claim

The presence of DAC-related chemistry establishes a structural distinction.

It does not independently establish:

• superiority
• better performance
• greater effectiveness
• greater safety

Relationship to Modified GRF Terminology

The structural difference between the 29-residue non-DAC analog and original albumin-binding CJC-1295 is discussed in CJC-1295 vs Modified GRF (1-29): Why the Names Should Be Distinguished.

Reading the FDA CJC-1295 Review

The FDA Pharmacy Compounding Advisory Committee materials for CJC-1295-related bulk substances distinguish multiple DAC and non-DAC molecular forms and provide a useful regulatory example of why exact CJC-1295 nomenclature matters.

The materials concern regulatory review of nominated bulk substances. They should not be interpreted as proof that any CJC-1295 form is approved, effective, safe, or appropriate for personal use.

Final Perspective

“CJC-1295 with DAC” identifies the albumin-binding molecular form associated with the original CJC-1295 development program.

The DAC-related design uses a chemically modified C-terminal lysine and maleimide-associated chemistry to permit covalent albumin association. This distinguishes the molecule from the shorter non-DAC Modified GRF (1-29) analog.

Accurate research coverage should specify the DAC structure, sequence, counterion form, analytical identity, and study context without treating the presence of DAC as evidence of effectiveness, superiority, safety, or personal-use suitability.